Other Events ·
Lantern Pharma Inc. announced on August 3, 2026, the establishment of Open-Medicine AI as a separate company to…
LTRNLantern Pharma Inc.
Lantern Pharma Inc. announced on August 3, 2026, the establishment of Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform for drug development. The new entity inherits the withZeta.ai technology and is supported by commercial licensing agreements executed between Lantern Pharma and Open-Medicine AI, which received Board approval. This strategic separation aligns with the framework of Lantern’s May 2026 registered direct financing led by Empery Asset Management. Lantern also highlighted its AI Center of Excellence in Bengaluru, India, established in Q1 2026, as a core operational hub for scaling the platform across oncology and other disease areas. The global AI drug discovery market is projected to exceed $10 billion by 2030. Lantern Pharma Inc. operates as a clinical-stage precision oncology company leveraging artificial intelligence and machine learning to transform cancer therapy development.